Clinical Trial of 0.0003% Calcitriol, 0.1% Tacrolimus, and Petrolatum for the Treatment of Pityriasis Alba

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Pityriasis alba (PA) is a frequent cause of consultation in tropical areas due to its chronic course, trend to relapse and aesthetic impact. Currently, no treatment is widely accepted. The objective is to assess the calcitriol and tacrolimus ointment efficacy in the treatment of PA compared with petrolatum. Twenty lesions on the face greater than 3 cm, in individuals of phototype IV-V, aged 3-18 years are going to be randomly assigned to receive petrolatum, calcitriol, and tacrolimus twice daily. No photoprotection is going to be indicated, and hygienic habits will not be modified. Patients will be evaluated at baseline and for 9 weeks, by means of Transepidermal Water Loss (TEWL), colorimetry, clinically and by photography control.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universidad Autonoma de San Luis Potosí
• Collaborator: Hospital Central "Dr. Ignacio Morones Prieto"
• Treatments: Calcitriol; Petrolatum; Tacrolimus; Vitamin D

Criteria

Inclusion Criteria:

• Diagnosis of Pityriasis alba with well defined lesions greater than 3 cm2.

Exclusion Criteria:

• Diagnosis of Atopic Dermatitis

• Skin disorders other than Pityriasis alba

• Systemic disorders

• Treatment during the last 8 weeks for this condition